These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31899220)

  • 21. Fourteen-day administration of corticosterone may induce detrusor overactivity symptoms.
    Wróbel A; Serefko A; Poleszak E; Rechberger T
    Int Urogynecol J; 2016 Nov; 27(11):1713-1721. PubMed ID: 27142032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
    Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
    Drake MJ; MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Herschorn S; Huang M; Stoelzel M; Siddiqui E
    Urology; 2017 Jun; 104():1-4. PubMed ID: 28322904
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
    Chen SF; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O53-O58. PubMed ID: 29380517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Clinical Efficacy and Complications of Duloxetine in Comparison to Solifenacin in the Treatment of Overactive Bladder Disease in Women: A Randomized Clinical Trial.
    Mirzaei M; Daneshpajooh A; Anvari SO; Dozchizadeh S; Teimorian M
    Urol J; 2021 Aug; 18(5):543-548. PubMed ID: 34346046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
    Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
    Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study).
    Alcántara-Montero A
    Actas Urol Esp; 2016 Nov; 40(9):593-594. PubMed ID: 27126125
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
    Vecchioli Scaldazza C; Morosetti C
    Urol Int; 2016; 97(3):325-329. PubMed ID: 27092789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
    Wang J; Zhou Z; Cui Y; Li Y; Yuan H; Gao Z; Zhu Z; Wu J
    Neurourol Urodyn; 2019 Jan; 38(1):22-30. PubMed ID: 30350884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
    de Greef-van der Sandt I; Newgreen D; Schaddelee M; Dorrepaal C; Martina R; Ridder A; van Maanen R
    Clin Pharmacol Ther; 2016 Apr; 99(4):442-51. PubMed ID: 26422298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
    Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.
    Kinjo M; Yamaguchi T; Tambo M; Okegawa T; Fukuhara H
    Urol Int; 2019; 102(3):331-335. PubMed ID: 30799398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
    Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
    Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug therapy for an overactive bladder.
    Thiagamoorthy G; Cardozo L; Srikrishna S
    Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice.
    Shen YC; Wang HJ; Chuang YC
    Int Urol Nephrol; 2018 Jul; 50(7):1219-1226. PubMed ID: 29882001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.